Phylo Inc, an applied AI research lab focused on agentic biology, announced on Tuesday a collaboration with Japan-based Chugai Pharmaceutical Co Ltd to deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows.

This partnership addresses a bottleneck in modern drug discovery, with analytical work behind every research decision slow and fragmented, forcing scientists to move constantly between disconnected tools, datasets, and methods. As a result, valuable biomedical data often sits static and underused.

Phylo says that as an Integrated Biology Environment, Biomni Lab brings best-in-class AI capabilities and hundreds of biomedical resources into one workspace, giving each Chugai scientist a collaborator across the discovery process. By connecting with proprietary research data inside Chugai's secure environment, Biomni agents can turn that data into stronger hypotheses and better-supported decisions, helping Chugai shorten discovery timelines and improve the probability of success in its programs. Biomni Lab will support Chugai's work across multiple areas of drug discovery, including single-cell analysis, human genetics, disease biology, and target evaluation.